(Q48721652)

14 February 2018

title

Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain (English)

1 reference

14 February 2018

2

Stein Kaasa

1 reference

14 February 2018

5

Olav Spigset

1 reference

14 February 2018

6

Ola Dale

1 reference

14 February 2018

author name string

Kristin Moksnes

series ordinal

1

1 reference

14 February 2018

Ørnulf Paulsen

series ordinal

3

1 reference

14 February 2018

Jan Henrik Rosland

series ordinal

4

1 reference

14 February 2018

publication date

29 February 2012

1 reference

14 February 2018

European Journal of Clinical Pharmacology

published in

1 reference

14 February 2018

volume

68

1 reference

14 February 2018

issue

8

1 reference

14 February 2018

page(s)

1147-1156

1 reference

14 February 2018

Morphine and alternative opioids in cancer pain: the EAPC recommendations

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Role of CYP2B6 in stereoselective human methadone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Rapid switching from morphine to methadone in cancer patients with poor response to morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Application issues in bioanalytical method validation, sample analysis and data reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Genetic modulation of the pharmacological treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Recruiting vulnerable populations for research: Revisiting the ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

High Interindividual Variability of Methadone Enantiomer Blood Levels to Dose Ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography–electrospray ionization–tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1228-3

Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

21 January 2018

1 reference

12 December 2020

Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study

1 reference

12 December 2020

The rediscovery of methadone for cancer pain management

1 reference

12 December 2020

Pain assessment: global use of the Brief Pain Inventory

1 reference

12 December 2020

Opioid plasma concentration during switching from morphine to methadone: preliminary data

1 reference

12 December 2020

Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

1 reference

12 December 2020

Human UGT2B7 catalyzes morphine glucuronidation

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain

1 reference

12 December 2020

Patient-controlled dose regimen of methadone for chronic cancer pain

1 reference

12 December 2020

Respiratory depression in a patient receiving oral methadone for cancer pain

1 reference

12 December 2020

How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial

1 reference

12 December 2020

Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects

1 reference

12 December 2020

Pharmacokinetics of continuous infusions of fentanyl in critically ill children.

1 reference

12 December 2020

Methadone for cancer pain

1 reference

12 December 2020

Important clinical pharmacologic considerations in the use of methadone in cancer patients

1 reference

12 December 2020

10.1007/S00228-012-1228-3

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018